Evidence map›Paper›PMID 36081760›Full record

ArticleAdvances in cell and gene therapy2022

Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T Cells.

Sung Hyun Lee, Yajing Hao, Tong Gui, Gianpietro Dotti, Barbara Savoldo, Fei Zou, Tal Kafri

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in cell and gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sung Hyun LeeGene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Yajing HaoDepartment of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA.
Tong GuiGene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Gianpietro DottiDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Barbara SavoldoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Fei ZouDepartment of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-6637-3593
Tal KafriGene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-9386-921X
University of North Carolina at Chapel Hill · US

Funding

Nonintegrating Lentiviral Vectors Towards Clinical TrialsR01DK058702 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAFRI, TAL · 2001 to 2019
$5.0M
Lentiviral Vector-Based Gene Therapy and The Host Genetic BackgroundR01HL128119 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAFRI, TAL · 2015 to 2018
$3.0M
NHLBI NIH HHS R01 HL128119NIDDK NIH HHS R01 DK058702
6 · The paper itself

Abstract

For more than a decade, genetically engineered autologous T-cells have been successfully employed as immunotherapy drugs for patients with incurable blood cancers. The active components in some of these game-changing medicines are autologous T-cells that express viral vector-delivered chimeric antigen receptors (CARs), which specifically target proteins that are preferentially expressed on cancer cells. Some of these therapeutic CAR expressing T-cells (CAR-Ts) are engineered via transduction with

Identifiers

PMID36081760
PMCPMC9450689
OpenAlexW4281967812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.